John S. Jarboe
YOU?
Author Swipe
View article: CSIG-10. MARCKS EFFECTOR DOMAIN PHOSPHORYLATION STATE AS A REGULATOR OF TUNNELING NANOTUBES IN GLIOBLASTOMA AND NORMAL HUMAN ASTROCYTE BIOLOGY
CSIG-10. MARCKS EFFECTOR DOMAIN PHOSPHORYLATION STATE AS A REGULATOR OF TUNNELING NANOTUBES IN GLIOBLASTOMA AND NORMAL HUMAN ASTROCYTE BIOLOGY Open
BACKGROUND Glioblastoma (GBM) is well known to interact with surrounding tumor and stromal cells in a variety of ways to maintain its pathogenicity. Emerging evidence has identified tunneling nanotubes (TNTs), dynamic actin-rich structures…
View article: MARCKS as a Target for Pathological Tunneling Nanotubes in Glioblastoma
MARCKS as a Target for Pathological Tunneling Nanotubes in Glioblastoma Open
During glioblastoma (GBM) progression, therapeutic resistance is influenced by a heterogeneous network of tumor- and tumor-promoting cells in the tumor microenvironment. Biological attacks against tumor cells (i.e. chemoradiotherapy) induc…
View article: Supplementary Methods and Figure Legends from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Methods and Figure Legends from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 125KB.
View article: Supplementary Figure 3 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 3 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 88KB, Supplemental Figure S3 shows U251 knockdown supplemental data including DNA repair and cell cycle.
View article: Supplementary Figure 1 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 1 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 24KB, Supplemental Figure S1 shows GBM cell line proliferation data.
View article: Supplementary Figure 1 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 1 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 24KB, Supplemental Figure S1 shows GBM cell line proliferation data.
View article: Supplementary Methods and Figure Legends from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Methods and Figure Legends from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 125KB.
View article: Data from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Data from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
Purpose: This study assessed whether myristoylated alanine-rich C-kinase substrate (MARCKS) can regulate glioblastoma multiforme (GBM) growth, radiation sensitivity, and clinical outcome.Experimental Design: MARCKS protein levels were anal…
View article: Supplementary Figure 2 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 2 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 148KB, Supplemental Figure S2 shows U251 knockdown supplemental data.
View article: Supplementary Figure 4 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 4 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 102KB, Supplemental Figure S4 shows DAPI stained U251 control and knockdown cells after radiation.
View article: Data from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Data from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
Purpose: This study assessed whether myristoylated alanine-rich C-kinase substrate (MARCKS) can regulate glioblastoma multiforme (GBM) growth, radiation sensitivity, and clinical outcome.Experimental Design: MARCKS protein levels were anal…
View article: Supplementary Figure 2 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 2 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 148KB, Supplemental Figure S2 shows U251 knockdown supplemental data.
View article: Supplementary Figure 4 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 4 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 102KB, Supplemental Figure S4 shows DAPI stained U251 control and knockdown cells after radiation.
View article: Supplementary Figure 3 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma
Supplementary Figure 3 from MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel Prognostic Factor for Glioma Open
PDF file, 88KB, Supplemental Figure S3 shows U251 knockdown supplemental data including DNA repair and cell cycle.
View article: Data from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Data from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies Open
Glioblastoma multiforme is the most common primary malignant brain tumor and despite treatment with surgery, radiation, and chemotherapy, the median survival of patients with glioblastoma multiforme is ∼1 year. Glioblastoma multiforme expl…
View article: Supplementary Figure 1 Legend from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Supplementary Figure 1 Legend from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies Open
Supplementary Figure 1 Legend from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
View article: Supplementary Figure 1 from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Supplementary Figure 1 from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies Open
Supplementary Figure 1 from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
View article: Supplementary Figure 1 from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Supplementary Figure 1 from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies Open
Supplementary Figure 1 from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
View article: Data from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Data from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies Open
Glioblastoma multiforme is the most common primary malignant brain tumor and despite treatment with surgery, radiation, and chemotherapy, the median survival of patients with glioblastoma multiforme is ∼1 year. Glioblastoma multiforme expl…
View article: Supplementary Figure 1 Legend from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
Supplementary Figure 1 Legend from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies Open
Supplementary Figure 1 Legend from Expression of Interleukin-13 Receptor α2 in Glioblastoma Multiforme: Implications for Targeted Therapies
View article: Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study
Pathologic Response Rates after Neoadjuvant Therapy for Sarcoma: A Single Institution Study Open
(1) Background: Pathologic necrosis of soft tissue sarcomas (STS) has been used to determine treatment response, but its relationship to neoadjuvant treatments remains indeterminate. In this retrospective, single institution study, we hypo…
View article: Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma
Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma Open
Glioblastoma harbors frequent alterations in receptor tyrosine kinases, phosphatidylinositol‑3 kinase (PI3K) and phosphatase and tensin homolog (PTEN) that dysregulate phospholipid signaling driven tumor proliferation and therapeutic resis…
View article: CSIG-10. MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE PHOSPHORYLATION ENHANCES THE GROWTH AND RADIATION RESISTANCE OF GLIOBLASTOMA
CSIG-10. MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE PHOSPHORYLATION ENHANCES THE GROWTH AND RADIATION RESISTANCE OF GLIOBLASTOMA Open
Glioblastoma (GBM) remains the most common and deadly form of adult glioma due to its tremendous proliferative capacity, invasive nature and high levels of therapeutic resistance. Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) is a…
View article: MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines
MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines Open
Lung cancer is the leading cause of cancer-associated mortality in the United States. Kinase hyperactivation is a known mechanism of tumorigenesis. The phosphorylation status of the plasma membrane-associated protein myristoylated alanine …
View article: The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization
The Effector Domain of MARCKS Is a Nuclear Localization Signal that Regulates Cellular PIP2 Levels and Nuclear PIP2 Localization Open
Translocation to the nucleus of diacylglycerol kinase (DGK)- ζ is dependent on a sequence homologous to the effector domain of Myristoylated Alanine Rich C-Kinase Substrate (MARCKS). These data would suggest that MARCKS could also localize…
View article: Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies
Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies Open
Osteolytic bone damage is a major cause of morbidity in several metastatic pathologies. Current therapies using bisphosphonates provide modest improvement, but cytotoxic side effects still occur prompting the need to develop more effective…